Phase 3
N=330
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
Papulopustular Rosacea
Bottom Line
View on ClinicalTrials.gov: NCT05343455 ↗Enrolled (actual)
330
Serious AEs
0.9%
Results posted
Dec 2024
Primary outcome: Primary: Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo. — 74; 22 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- DFD-29 (Drug); Doxycycline (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Journey Medical Corporation
- Primary completion
- Jun 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo. |
74; 22 | — |
| PRIMARY Change in Total Inflammatory Lesion Count Compared to Placebo. |
-18.1; -11.2 | — |
| SECONDARY IGA Treatment Success Compared to Doxycycline. |
74; 39 | — |
| SECONDARY Change in Total Inflammatory Lesion Count Compared to Doxycycline. |
-18.1; -14.6 | — |
| SECONDARY Clinician's Erythema Assessment (CEA) Change Compared to Placebo. |
30; 10 | — |
Summary
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are diagnosed with moderate to severe papulopustular rosacea will be randomized in a 3:3:2 ratio to DFD-29 (40 mg), Doxycycline capsules 40 mg, or Placebo once daily for 16 weeks. Of the 320 subjects, approximately 160 subjects are planned to be enrolled at 15 sites in the US, while the remaining subjects are to be enrolled at 14 sites in the EU.
Eligibility Criteria
Key Inclusion Criteria
- Male and female subjects aged 18 years and above.
- Subjects must be in good general health as determined by the investigator and supported by the medical history.
- Subjects must have a clinical diagnosis of papulopustular rosacea with IGA grade 3 (moderate) or IGA grade 4 (severe) at Baseline.
- Subjects must have 15 to 60 (both inclusive) inflammatory lesions (papules and pustules) of rosacea over the face at Baseline.
- Subjects must have not more than 2 nodules or cysts at Baseline.
Key Exclusion Criteria
- Female subjects who are pregnant or nursing or planning to become pregnant during the study.
- Male subjects whose female partner is planning to conceive a child.
- Clinically significant abnormal laboratory test results that, in the opinion of the investigator, would compromise the subject's safety or ability to participate in the trial.
- History of organ transplant requiring immunosuppression, HIV, or other immune compromised state.
- History of lupus-like syndrome, autoimmune hepatitis, vasculitis, or serum sickness.
- Any clinically significant condition or situation other than the condition being studied that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study.
Data sourced from ClinicalTrials.gov (NCT05343455). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.